-
Sector Analysis
Overweight and Obesity: Epidemiology Report and Forecast to 2035
Obesity is a chronic disease characterized by the accumulation of excess body fat. Individuals living with obesity may undergo metabolic dysfunction on account of excess adipose tissue. The diagnostic criteria for obesity are met by a body mass index (BMI) of 30kg/m2 or more (NIH, 2022a). This can lead to a state of chronic systemic inflammation, as well as a predisposition to comorbidities such as diabetes and cardiovascular disease. Clinical interventions aim to manage obesity by encouraging patient behavioral change,...
-
Product Insights
Diabetic Foot Ulcers: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Diabetic Foot Ulcers - Global Clinical Trials Review, 2026" provides an overview of Diabetic Foot Ulcers Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Hyperlipidemia: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hyperlipidemia - Global Clinical Trials Review, 2026" provides an overview of Hyperlipidemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperlipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Global Clinical Trials Review, 2026" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Hyperuricemia - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hyperuricemia - Global Clinical Trials Review, 2026" provides an overview of Hyperuricemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperuricemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Phenylketonuria (PKU) - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Phenylketonuria (PKU) - Global Clinical Trials Review, 2025" provides an overview of Phenylketonuria (PKU) Clinical trials scenario. This report provides top line data relating to the clinical trials on Phenylketonuria (PKU). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Diabetic Macular Edema (DME): Epidemiology Forecast to 2034
Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level...
-
Product Insights
Diabetic Peripheral Neuropathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Peripheral Neuropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the CKD-HPT, HP and HK market through 2034. • There will be an overall increase in the diagnosed prevalent cases of CKD- HPT, HP and HK in the 7MM across the forecast period. • Across the 7MM, the mainstay treatment for HPT, HP, and HK involves phosphate binders, calcimimetics, and potassium binders • Significant clinical and environmental unmet needs remain in the CKD- HPT, HP...
-
Sector Analysis
Hypoglycemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypoglycemia Therapeutics. • In 2024 and 2029, India is estimated to have the highest number of diagnosed incident cases of hypoglycemia, representing a large portion of global cases. • Novo Nordisk’s GlucaGen (glucagon hypokit) and Eli Lilly’s Glucagon had been the primary marketed glucagons for decades. • The hypoglycemia pipeline holds 16 molecules, with no assets in the pre-registration stage, three assets in Phase III development,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.